Market research
HGF2.F Catalyst Biosciences, Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 16.6
- Dividend yield
- Not available
- Beta
- 1.29
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 16.6
- Dividend yield
- Not available
- Beta
- 1.29
About
About Catalyst Biosciences, Inc
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Research context
Catalyst Biosciences, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HGF2.F discussion.
5 years, 7 months ago
Catalyst Biosciences, Inc is currently in a long term downtrend where the price is trading 21.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
Catalyst Biosciences, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has dropped by 38.9% to $-19M since the same quarter in the previous year.
Finally, its free cash flow fell by 173.9% to $-22M since the same quarter in the previous year.
Based on the above factors, Catalyst Biosciences, Inc gets an overall score of 2/5.